Navigation Links
Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
Date:12/16/2008

cts for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

    For further information contact:

    Investor & Media Relations
    Ian Stone                            Robert Flamm, Ph.D.
    Russo Partners LLC                   Russo Partners LLC
    Tel: (619) 814-3510                  Tel: (212) 845-4226
    Fax: (619) 955-5318                  Email:
    Email:                               robert.flamm@russopartnersllc.com
    ian.stone@russopartnersllc.com       www.russopartnersllc.com

This News Release contains certain forward-looking statements and information regarding Helix's drug development plans, which statements and information can be identified by the use of forward-looking terminology such as "intends", "plans", "expects", "pending", "to occur", "objective", "believes", "on track", "is being designed", "proceeding", "intention", "to seek", "projects", "anticipates", "2009", "2010", "2012", "assuming", "continuing", "with a view to", "if", "developing", or variations thereon, or that events "could" or "would" occur or be achieved, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future, are not historical facts, and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: Helix's need for further financing, which may not be available; uncertainty whether the Company's products under development, includin
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. CSL Behrings Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance
2. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
3. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
4. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
5. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
7. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
8. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
9. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
10. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
11. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... steam over the five years to 2014. Industry operators ... first time during the period, as well as establish ... growth is due in large part to its novelty; ... 2005. Nevertheless, in that time, industry operators have been ...
(Date:9/19/2014)... 19, 2014 Follow us ... surgical techniques, and immunosuppressant drugs to prevent rejection, ... several chronic diseases related to the heart, kidneys, ... tissue transplantation have phenomenally revolutionized the survival rate ... today represents a pivotal medical intervention for thousands ...
(Date:9/19/2014)... well in infertile land, and bear many beans that ... because most legumes have a symbiotic relationship with bacteria, ... and then supply the host plant with ammonia as ... called nodules in their roots. However, if too many ... growth of the plants, because the energy cost of ...
(Date:9/19/2014)... Lifeinsure.biz has released a new blog post presenting 5 ... medical examinations. , Life insurance riders can drive ... more advantageous. Clients can read the newly released blog ... a no medical exam life insurance policy. , ... purchase, however it is more expensive. Life insurance rates ...
(Date:9/19/2014)... September 19, 2014 Ticket Down ... for his 2014 concert tour. Concertgoers can add ... business, there are a handful of artists that are considered ... in Saginaw, MichIgan, Wonder has been a force in the ... in the music business, he has released 23 studio albums, ...
Breaking Medicine News(10 mins):Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Long-distance communication from leaves to roots 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3
... devastating brain injury that has wiped out many of ... other peoples feelings and intentions, according to a joint ... Centre for Aging and the Brain, and York Universitys ... published in the Nov. 23, 2007 issue of Science, ...
... sleepiness, experts say, , , THURSDAY, Nov. 22 (HealthDay News) ... Thanksgiving feast aren,t rare, and experts say a number ... , It may have to do with the traditional ... a chemical known to promote sleepiness, said Donna Arand, ...
... future treatment of breast cancer have been identified by a ... the online open access journal Breast Cancer Research may focus ... , A team led by Professor Mitch Dowsett, Head of ... London and Surrey, together with colleagues from the USA, Switzerland ...
... CHICAGO, Nov. 21 The Female Health Company,(Amex: ... The Wall Street,Analyst Forum 18th Annual Analyst Conference on ... York City (on 43rd Street between 5th and,6th). The ... will,present at the conference at 11:50 a.m. Eastern Time ...
... mean more ozone, and more strain on hearts, researchers ... temperatures and high ozone levels work together to boost ... , They believe that global warming -- which brings ... the number of people who die of cardiovascular events. ...
... PICK: Pregnant women pass on the effects of smoking ... effects on fetal development. A new study in mice ... Toronto, Canada, now adds the possibility that smoking before ... of female offspring to the long list of possible ...
Cached Medicine News:Health News:People with rare type of memory loss still sensitive to others, study shows 2Health News:People with rare type of memory loss still sensitive to others, study shows 3Health News:There's More Than Turkey Behind Holiday Yawns 2Health News:Found in translation: Prioritizing research questions in breast cancer 2Health News:The Female Health Company to Present at Wall Street Analyst Forum Wednesday, November 28, 2007 2Health News:Global Warming May Trigger Rise in Heart Deaths 2Health News:Global Warming May Trigger Rise in Heart Deaths 3Health News:JCI table of contents: Nov. 21, 2007 2Health News:JCI table of contents: Nov. 21, 2007 3Health News:JCI table of contents: Nov. 21, 2007 4Health News:JCI table of contents: Nov. 21, 2007 5Health News:JCI table of contents: Nov. 21, 2007 6Health News:JCI table of contents: Nov. 21, 2007 7Health News:JCI table of contents: Nov. 21, 2007 8Health News:JCI table of contents: Nov. 21, 2007 9Health News:JCI table of contents: Nov. 21, 2007 10
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Target illumination for day and night testing. Glare luminance distance. The Optec 3500 remote control offers flexible positioning during test administration. Each vision tester includes 12 tests sli...
... The CSV- lOOOHGT instrument provides standardized glare testing. ... Vectorvision test faces for the evaluation of glare ... is precisely calibrated to simulate two on-coming halogen ... feet. The glare level can be adjusted to ...
Ruler S/Steel....
Medicine Products: